Page 91 - 2023 Taiwan Food and Drug Administration Annual Report
P. 91

6Special Edition

▍	Achievements and Benefits                      II. Internationally recognized
                                                    capabilities of national
I. Enhanced capability in                           laboratories in preparing
  preparing national standards                      standards
  to deploy advanced epidemic
  control strength                                     In order to assure the credibility of our
                                                 national standards, TFDA invited international
      In response to COVID-19, supplying         control laboratories in advanced countries
safe and effective anti-pandemic resources to    such as the NIBSC in the UK to conduct
the public is the unchanged principle followed   the collaborative study in compliance with
by TFDA. Our national laboratories devote        applicable WHO guidelines to the preparation
themselves to prepare biological SARS-           of international biological standards where
CoV-2 standards immediately, including the       they could not only help one another define
new generation of SARS-CoV-2 national            international or national standards but also
standard, containing the Wuhan strain and 5      cooperate with and supervise one another so
different variants (alpha, beta, gamma, delta,   that Taiwan is capable of preparing standards
and omicron strain) and the antigen standard     comparable to our international counterparts.
for the quality control of COVID-19 rapid test.  In addition, the UK NIBSC is an international
Furthermore, the antigen standard has been       laboratory for preparing WHO biological
used to ensure the quality of 20 brands (more    standards. In the past, the world’s topnotch
than 50 batches) of COVID-19 rapid tests.        laboratories in related fields were invited to
In addition, TFDA published the method for       join the collaborative study of international
testing “COVID-19 rapid antigen test” and        standards. TFDA is one of the few Asian
it makes the academic and biotech industrial     national laboratories invited to take part in
laboratories be able to gain the techniques      the collaborative study of the WHO first
required for COVID-19 rapid test development     generation of SARS-CoV-2 international
and standardization. It also harmonizes          standards and again in 2023 for the second
differences among laboratories and boosts the    generation, indicating that the capabilities of
capacity to test the quality of rapid tests.     our national laboratories are recognized by the
                                                 international community.

                                                                                                  89
   86   87   88   89   90   91   92   93   94   95   96